130 related articles for article (PubMed ID: 36346016)
1. Fraxetin suppresses the proliferation, migration, and invasion of ovarian cancer cells by inhibiting the TLR4/STAT3 signaling pathway.
Xu R; Ruan Y; Zhang L; Gu Y; Liu M
Immunopharmacol Immunotoxicol; 2023 Jun; 45(3):287-294. PubMed ID: 36346016
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib.
Liu L; Zhang Z; Zhang G; Wang T; Ma Y; Guo W
J Transl Med; 2020 Sep; 18(1):357. PubMed ID: 32951601
[TBL] [Abstract][Full Text] [Related]
3. OTX1 silencing suppresses ovarian cancer progression through inhibiting the JAK/STAT signaling.
Zhang Q; Li X; Ren L; Gu X; Xiao N; Li N
Tissue Cell; 2023 Jun; 82():102082. PubMed ID: 37027968
[TBL] [Abstract][Full Text] [Related]
4. Fraxetin Suppresses Proliferation of Non-Small-Cell Lung Cancer Cells via Preventing Activation of Signal Transducer and Activator of Transcription 3.
Zhang Y; Wang L; Deng Y; Zhao P; Deng W; Zhang J; Luo J; Li R
Tohoku J Exp Med; 2019 May; 248(1):3-12. PubMed ID: 31080186
[TBL] [Abstract][Full Text] [Related]
5. Irisin reverses the IL-6 induced epithelial-mesenchymal transition in osteosarcoma cell migration and invasion through the STAT3/Snail signaling pathway.
Kong G; Jiang Y; Sun X; Cao Z; Zhang G; Zhao Z; Zhao Y; Yu Q; Cheng G
Oncol Rep; 2017 Nov; 38(5):2647-2656. PubMed ID: 29048621
[TBL] [Abstract][Full Text] [Related]
6. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
7. Long Noncoding RNA HOST2 Promotes Epithelial-Mesenchymal Transition, Proliferation, Invasion and Migration of Hepatocellular Carcinoma Cells by Activating the JAK2-STAT3 Signaling Pathway.
Wu Y; Yuan T; Wang WW; Ge PL; Gao ZQ; Zhang G; Tang Z; Dang XW; Zhao YF; Zhang JY; Jiang GZ
Cell Physiol Biochem; 2018; 51(1):301-314. PubMed ID: 30453302
[TBL] [Abstract][Full Text] [Related]
8. M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway.
Yao RR; Li JH; Zhang R; Chen RX; Wang YH
World J Surg Oncol; 2018 Jan; 16(1):9. PubMed ID: 29338742
[TBL] [Abstract][Full Text] [Related]
9. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
Guo Y; Xiao Y; Guo H; Zhu H; Chen D; Wang J; Deng J; Lan J; Liu X; Zhang Q; Bai Y
Aging (Albany NY); 2021 Jul; 13(14):18545-18563. PubMed ID: 34320467
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
[TBL] [Abstract][Full Text] [Related]
11. Alpinetin inhibits proliferation and migration of ovarian cancer cells via suppression of STAT3 signaling.
Zhao X; Guo X; Shen J; Hua D
Mol Med Rep; 2018 Oct; 18(4):4030-4036. PubMed ID: 30132572
[TBL] [Abstract][Full Text] [Related]
12. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
13. Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling.
Liu W; Wang X; Wang L; Mei Y; Yun Y; Yao X; Chen Q; Zhou J; Kou B
Int J Med Sci; 2022; 19(6):965-974. PubMed ID: 35813296
[TBL] [Abstract][Full Text] [Related]
14. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA Inhibits Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Modulation of STAT3-CCL2 Signaling.
Huang SY; Chang SF; Liao KF; Chiu SC
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28757590
[TBL] [Abstract][Full Text] [Related]
16. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
17. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.
Gao H; Wang W; Li Q
Cancer Biol Ther; 2022 Dec; 23(1):369-377. PubMed ID: 35491899
[TBL] [Abstract][Full Text] [Related]
18. [ZFP36L1 inhibits proliferation, invasion and migration of human breast cancer cells by inducing epithelial-mesenchymal transition through STAT3/p-STAT3 signaling pathway].
Zhang F; Qi G; Ding K; Liu J; Chen M; Lin M; Zhou F
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Aug; 38(8):721-726. PubMed ID: 35851086
[TBL] [Abstract][Full Text] [Related]
19. Fraxetin exerts anticancer effect in glioma by suppressing MiR-21-3p.
Yao H; Li X; Pan X; Xu J; Zhao S; Su Z; Qiu S
Drug Dev Res; 2022 Apr; 83(2):501-511. PubMed ID: 34523750
[TBL] [Abstract][Full Text] [Related]
20. PMA treated THP-1-derived-IL-6 promotes EMT of SW48 through STAT3/ERK-dependent activation of Wnt/β-catenin signaling pathway.
Gao S; Hu J; Wu X; Liang Z
Biomed Pharmacother; 2018 Dec; 108():618-624. PubMed ID: 30243096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
